β

Adrenergic beta-Antagonists / pharmacology Animals Cell Proliferation / drug effects Cell Survival / drug effects Coculture Techniques Disease Models, Animal Male Melanoma, Experimental / drug therapy Mice Mice, Inbred C57BL Receptors, Adrenergic, beta-3 / genetics Skin Neoplasms / drug therapy Tumor Cells, Cultured

Journal

British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536

Informations de publication

Date de publication:
07 2019
Historique:
received: 03 10 2018
revised: 02 02 2019
accepted: 22 02 2019
pubmed: 16 3 2019
medline: 22 8 2020
entrez: 16 3 2019
Statut: ppublish

Résumé

Stress-related catecholamines have a role in cancer and β-adrenoceptors; specifically, β A mouse model of melanoma in which syngeneic B16-F10 cells were injected in C57BL-6 mice was used to evaluate the effect of β-adrenoceptor blockade on the number and activity of immune cell sub-populations (Treg, NK, CD8, MDSC, macrophages, and neutrophils). Pharmacological and molecular approaches with β-blockers (propranolol and SR59230A) and specific β-adrenoceptor siRNAs targeting β Only β Our data suggest that β This article is part of a themed section on Adrenoceptors-New Roles for Old Players. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.14/issuetoc.

Sections du résumé

BACKGROUND AND PURPOSE
Stress-related catecholamines have a role in cancer and β-adrenoceptors; specifically, β
EXPERIMENTAL APPROACH
A mouse model of melanoma in which syngeneic B16-F10 cells were injected in C57BL-6 mice was used to evaluate the effect of β-adrenoceptor blockade on the number and activity of immune cell sub-populations (Treg, NK, CD8, MDSC, macrophages, and neutrophils). Pharmacological and molecular approaches with β-blockers (propranolol and SR59230A) and specific β-adrenoceptor siRNAs targeting β
KEY RESULTS
Only β
CONCLUSIONS AND IMPLICATIONS
Our data suggest that β
LINKED ARTICLES
This article is part of a themed section on Adrenoceptors-New Roles for Old Players. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.14/issuetoc.

Identifiants

DOI: 10.1111/bph.14660 PMID: 30874296 PMC: PMC6592854
pubmed: 30874296
doi: 10.1111/bph.14660
pmc: PMC6592854
doi:

Substances chimiques

Adrenergic beta-Antagonists 0
Receptors, Adrenergic, beta-3 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2509-2524

Informations de copyright

© 2019 The British Pharmacological Society.

Références

Science. 2013 Jul 12;341(6142):1236361
pubmed: 23846904
Br J Pharmacol. 2018 Apr;175(7):987-993
pubmed: 29520785
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106
pubmed: 29149325
Br J Pharmacol. 2010 Aug;160(7):1577-9
pubmed: 20649561
Naunyn Schmiedebergs Arch Pharmacol. 2014 Jun;387(6):533-43
pubmed: 24599317
J Mol Med (Berl). 2013 Dec;91(12):1407-19
pubmed: 23907236
Cancer Res. 2015 Nov 1;75(21):4441-5
pubmed: 26475869
Br J Pharmacol. 2009 Oct;158(3):638-51
pubmed: 19764983
Br J Pharmacol. 2017 Dec;174 Suppl 1:S225-S271
pubmed: 29055036
Trends Immunol. 2010 Jun;31(6):212-9
pubmed: 20452821
Am J Transl Res. 2016 Nov 15;8(11):5059-5070
pubmed: 27904707
PLoS One. 2011 Apr 29;6(4):e19246
pubmed: 21559428
Eur J Cancer. 2013 Dec;49(18):3863-71
pubmed: 23942335
Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9
pubmed: 14730417
Mol Pharmacol. 2007 Nov;72(5):1359-68
pubmed: 17717109
Neuroimmunomodulation. 2012;19(2):69-78
pubmed: 22248722
Oncoimmunology. 2012 Oct 1;1(7):1135-1145
pubmed: 23170260
Melanoma Res. 2017 Jun;27(3):268-270
pubmed: 28346289
Semin Cancer Biol. 2015 Dec;35 Suppl:S185-S198
pubmed: 25818339
Brain Behav Immun. 2009 Feb;23(2):267-75
pubmed: 18996182
Br J Pharmacol. 2019 Jul;176(14):2509-2524
pubmed: 30874296
Eur J Immunol. 2013 Apr;43(4):1001-12
pubmed: 23436577
Cell Immunol. 2011;270(1):80-7
pubmed: 21600570
Brain Behav Immun. 2007 Aug;21(6):736-45
pubmed: 17467231
Biochim Biophys Acta Mol Cell Res. 2017 Oct;1864(10):1769-1784
pubmed: 28723418
Eur J Immunol. 2016 Aug;46(8):1948-58
pubmed: 27222010
Br J Dermatol. 2014 Apr;170(4):930-8
pubmed: 24593055
Oncotarget. 2017 Oct 31;8(62):106132-106142
pubmed: 29285320
J Appl Physiol (1985). 1995 Apr;78(4):1442-6
pubmed: 7615453
J Immunol. 2002 Jan 15;168(2):689-95
pubmed: 11777962
Arch Intern Med. 2011 Apr 25;171(8):779-81
pubmed: 21518948
Naunyn Schmiedebergs Arch Pharmacol. 2006 Nov;374(2):99-105
pubmed: 17028849
J Invest Dermatol. 2015 Feb;135(2):525-531
pubmed: 25178102
Br J Pharmacol. 2017 Dec;174 Suppl 1:S1-S16
pubmed: 29055037
Oncoimmunology. 2012 Nov 1;1(8):1433-1434
pubmed: 23243619
Naunyn Schmiedebergs Arch Pharmacol. 2015 Dec;388(12):1317-31
pubmed: 26285646
Nat Commun. 2013;4:1403
pubmed: 23360994
Amino Acids. 2013 Jul;45(1):55-71
pubmed: 22160285
Clin Breast Cancer. 2015 Dec;15(6):426-31
pubmed: 26516037
Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2273-9
pubmed: 21933972
Lancet Oncol. 2004 Apr;5(4):254-8
pubmed: 15050959
J Pharmacol Exp Ther. 1999 Aug;290(2):649-55
pubmed: 10411574
Scand J Immunol. 1988 Jun;27(6):673-8
pubmed: 3393847
J Cell Mol Med. 2012 Apr;16(4):920-6
pubmed: 21722303
Cell Immunol. 2009;254(2):149-54
pubmed: 18835598
Nature. 2011 Jul 13;475(7355):226-30
pubmed: 21753853
Br J Pharmacol. 2017 Dec;174 Suppl 1:S272-S359
pubmed: 29055034
Oncoimmunology. 2017 Dec 21;7(3):e1405205
pubmed: 29399407
Clin Cancer Res. 2012 Mar 1;18(5):1201-6
pubmed: 22186256
Nat Med. 2006 Aug;12(8):939-44
pubmed: 16862152
Drugs Today (Barc). 2018 Feb;54(2):103-122
pubmed: 29637937
Lab Invest. 2013 Mar;93(3):279-90
pubmed: 23318885
Br J Pharmacol. 2005 Feb;144(3):317-22
pubmed: 15655528
Naunyn Schmiedebergs Arch Pharmacol. 2007 Feb;374(5-6):385-98
pubmed: 17211601
Oncotarget. 2015 Mar 10;6(7):4615-32
pubmed: 25474135
Exp Physiol. 2000 Nov;85(6):681-5
pubmed: 11187963
J Immunol. 2010 Mar 1;184(5):2449-57
pubmed: 20124103
Cancer Cell. 2009 Sep 8;16(3):183-94
pubmed: 19732719
Brain Behav Immun. 1996 Jun;10(2):77-91
pubmed: 8811932
Br J Pharmacol. 2019 Jul;176(14):2496-2508
pubmed: 30471093
Oncogene. 2018 May;37(22):2953-2966
pubmed: 29515233
Brain Behav Immun. 2002 Jun;16(3):227-46
pubmed: 12009684
Br J Pharmacol. 2017 Dec;174 Suppl 1:S17-S129
pubmed: 29055040
Mol Biotechnol. 2003 Sep;25(1):19-30
pubmed: 13679631
Nat Rev Cancer. 2015 Sep;15(9):563-72
pubmed: 26299593
Clin Pharmacol Ther. 1989 Oct;46(4):429-39
pubmed: 2551559
Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1478-83
pubmed: 23766387
Immunity. 2017 Jan 17;46(1):15-28
pubmed: 28099862
Cancer Immunol Res. 2018 Jan;6(1):98-109
pubmed: 29146881
N Engl J Med. 2018 Aug 23;379(8):722-730
pubmed: 30134131

Auteurs

Maura Calvani (M)

Oncohematology Unit, Department of Pediatric Oncology, Meyer University Children's University Hospital, Florence, Italy.

Gennaro Bruno (G)

Department of Health Sciences, University of Florence, Florence, Italy.

Massimo Dal Monte (M)

Department of Biology, Unit of General Physiology, University of Pisa, Pisa, Italy.
ORCID: 0000-0002-5181-4456

Romina Nassini (R)

Department of Health Sciences, University of Florence, Florence, Italy.
ORCID: 0000-0002-9223-8395

Filippo Fontani (F)

Department of Health Sciences, University of Florence, Florence, Italy.

Arianna Casini (A)

Division of Immunology, Section of Pediatrics, Meyer University Children's Hospital, Florence, Italy.

Lorenzo Cavallini (L)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Matteo Becatti (M)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.

Francesca Bianchini (F)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.

Francesco De Logu (F)

Department of Health Sciences, University of Florence, Florence, Italy.

Giulia Forni (G)

Metabolic and Newborn Screening Clinical Unit, Department of Neurosciences, Meyer University Children's University Hospital, Florence, Italy.

Giancarlo la Marca (G)

Metabolic and Newborn Screening Clinical Unit, Department of Neurosciences, Meyer University Children's University Hospital, Florence, Italy.

Lido Calorini (L)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.

Paola Bagnoli (P)

Department of Biology, Unit of General Physiology, University of Pisa, Pisa, Italy.

Paola Chiarugi (P)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.

Alberto Pupi (A)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.

Chiara Azzari (C)

Department of Health Sciences, University of Florence, Florence, Italy.

Pierangelo Geppetti (P)

Department of Health Sciences, University of Florence, Florence, Italy.

Claudio Favre (C)

Oncohematology Unit, Department of Pediatric Oncology, Meyer University Children's University Hospital, Florence, Italy.

Luca Filippi (L)

Neonatal Intensive Care Unit, Medical Surgical Fetal-Neonatal Department, Meyer University Children's Hospital, Florence, Italy.
ORCID: 0000-0001-5310-9147

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Meal Timing and Anthropometric and Metabolic Outcomes: A Systematic Review and Meta-Analysis.

Hiu Yee Liu, Ashley A Eso, Nathan Cook et al.
1.00
Humans Meals Time Factors Female Adult

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents adrénergiques › Antagonistes adrénergiques › Antagonistes bêta-adrénergiques › β
questionsmedicales.fr › Eucaryotes › Animaux › β
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › β
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Survie cellulaire › β
questionsmedicales.fr › Techniques d'investigation › Techniques in vitro › Techniques de culture › Techniques de coculture › β
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › β
questionsmedicales.fr › Techniques d'investigation › Modèles animaux › Tumeurs expérimentales › Mélanome expérimental › β
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › β
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée C57BL › β
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs catécholaminergiques › Récepteurs adrénergiques › Récepteurs bêta-adrénergiques › Récepteurs bêta-3 adrénergiques › β
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Tumeurs cutanées › β
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › β